Opinion Paper

Michele Bartoletti*, Massimo Antonelli, Francesco Arturo Bruno Blasi, Ivo Casagrande, Arturo Chieragato, Roberto Fumagalli, Massimo Girardis, Filippo Pieralli, Mario Plebani, Gian Maria Rossolini, Massimo Sartelli, Bruno Viaggi, Pierluigi Viale, Claudio Viscoli and Federico Pea

Procalcitonin-guided antibiotic therapy: an expert consensus

<https://doi.org/10.1515/cclm-2018-0259>

Received March 12, 2018; accepted March 23, 2018; previously published online June 6, 2018

Abstract

Background: Procalcitonin (PCT) is a useful biomarker of bacterial infection and its use is associated to reduced duration of antibiotic therapy in the setting of intensive care medicine. To address the need of practical guidance for the use of PCT in various clinical settings, a group of experts was invited to participate at a consensus process with the aims of defining the rationale for appropriate use of PCT and for improving the management of critically ill patients with sepsis.

Methods: A group of 14 experts from anesthesiology and critical care, infectious diseases, internal medicine, pulmonology, clinical microbiology, laboratory medicine,

clinical pharmacology and methodology provided expert opinion through a modified Delphi process, after a comprehensive literature review.

Results: The appropriateness of use of PCT in terms of diagnosis, prognosis and antimicrobial stewardship was assessed for different scenarios or settings such as management of infection in the emergency department, regular wards, surgical wards or in the intensive care unit. Similarly, appropriateness and timing of PCT measurement were evaluated. All the process consisted in three Delphi rounds.

Conclusions: PCT use is appropriate in algorithms for antibiotic de-escalation and discontinuation. In this case, reproducible, high sensitive assays should be used. However, initiation or escalation of antibiotic therapy in specific scenarios, including acute respiratory infections, should not be based solely on PCT serum levels. Clinical and radiological findings, evaluation of severity of illness

***Corresponding author: Michele Bartoletti, MD**, Infectious Diseases Unit, Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 11, 40138 Bologna, Italy, Phone: +390512143199, Fax: +39051343500, E-mail: michele.bartoletti4@unibo.it, <http://orcid.org/0000-0002-1099-3283>

Massimo Antonelli: UOC Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica (UOC) Fondazione Policlinico Universitario A. Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy

Francesco Arturo Bruno Blasi: Department of Pathophysiology and Transplantation, Università degli studi di Milano, UOC broncopneumologia, IRCCS Fondazione, “Cà Granda” Policlinico, Milan, Italy

Ivo Casagrande: Dipartimento di Emergenza ed Accettazione, Azienda Ospedaliera “Santi Antonio e Biagio e C. Arrigo”, Alessandria, Italy

Arturo Chieragato: Neurorisanimazione, Ospedale Niguarda Ca' Granda, Milan, Italy

Roberto Fumagalli: Anestesia e rianimazione I, Ospedale Niguarda Ca' Granda, Milan, Italy

Massimo Girardis: Anestesia e Rianimazione I, Dipartimento chirurgia generale e specialità chirurgiche, Azienda Ospedaliero-Universitaria di Modena – Policlinico, Modena, Italy

Filippo Pieralli: Subintensiva di Medicina, – Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Mario Plebani: UO Medicina di Laboratorio, Azienda Ospedale-Università di Padova, Padua, Italy. <http://orcid.org/0000-0002-0270-1711>

Gian Maria Rossolini: Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze e SOD Microbiologia e Virologia-Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Massimo Sartelli: UO Chirurgia Generale, Dipartimento Chirurgia maggiore oncologica, Ospedale di Macerata, Macerata, Italy

Bruno Viaggi: NeuroAnestesia e Rianimazione, Dipartimento di Anestesia, Azienda Ospedaliero Universitaria Careggi, Firenze, Florence, Italy

Pierluigi Viale: Infectious Diseases Unit, Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Claudio Viscoli: Clinica Malattie Infettive, Università di Genova e Ospedale Policlinico San Martino, IRCCS per l'Oncologia, Genova, Italy

Federico Pea: Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUIUD, Udine, Italy; and Department of Medicine, University of Udine, Udine, Italy

and of patient's characteristics should be taken into proper account in order to correctly interpret PCT results.

Keywords: antibiotic therapy; antimicrobial stewardship; expert consensus; procalcitonin.

Introduction

The growing prevalence of antibiotic resistance is a global emergence. It is estimated that, by 2050, 10 million people will die every year due to antimicrobial resistance [1]. The reason of antibiotic crisis relies on several factors, including the antibiotic misuse or overuse. In fact, it is reported that treatment indication, doses or duration of treatment are incorrect in up to 30%–50% of antibiotic prescriptions [2–4]. The over prescription of antibiotic, in turn, may be associated to increased costs, adverse events and prolonged length of hospitalization. On the other hand, early antibiotic prescription may be necessary in patients with sepsis or septic shock [5]. In several studies on critically ill patients, any delay of adequate antibiotic treatment was associated to an increased risk for mortality [6, 7].

Procalcitonin (PCT) is a calcitonin precursor ubiquitously distributed in the human organs and tissues [8]. Several characteristics have conferred to PCT a key role as a biomarker of bacterial sepsis. First, during the acute phase of sepsis, PCT production is commonly upregulated [9]. Second, peak levels of PCT after a bacterial insult are usually achieved very rapidly with values that are correlated with the intensity of the stimulation [10]. Third, PCT has a short half-life, and therefore levels usually drop rapidly after the end of the insult. According with these characteristics, previous studies indicate that PCT is a marker of bacterial infection with good sensitivity and specificity [9, 11, 12]. In addition, use of PCT was associated to lower antibiotic use, being able to rule out bacterial infectious processes or to identify patients eligible to early antibiotic de-escalation or discontinuation [13, 14].

Despite the aforementioned encouraging results, the proper use of PCT should be further addressed in several specific clinical situations. More specifically, the effect of implementation of PCT algorithms in different clinical scenarios to improve antibiotic use and outcomes and to limit cost remains unknown [15]. To address the need of practical guidance for the use of PCT in various clinical settings, a group of experts was invited to participate at a consensus process with the aims of defining the rationale for appropriate use of PCT and for improving the management of critically ill patients with sepsis.

Materials and methods

The consensus was managed by a multidisciplinary team, including experts in anesthesiology and critical care, infectious diseases, internal medicine, pulmonology, clinical microbiology, laboratory medicine, clinical pharmacology and methodology (Table 1). Expert opinion from the board was obtained through a modified Delphi process [16].

Consensus process

The process was conducted on January 2017. The opinion of experts about the appropriateness of use of PCT was assessed in different clinical settings. In addition, the judgment of experts about the role of PCT as a diagnostic test, prognostic marker or as an antimicrobial stewardship tool was assessed as well. It consisted in a series of rounds as follows. During the first round, the experts were invited to share their opinion based on their knowledge and experiences. Thereafter, a free discussion and a comprehensive review of the literature was promoted. During the literature review process, only studies using high sensitive assays (B·R·A·H·M·S· PCT antibodies assays) were included. These assays have shown reproducibility of results and great reliability.

On the first round, two experts, one of infectious disease and the other of clinical pharmacology, developed a list of questions and of possible predefined answers, which had to be submitted to the panel. The questions were directed to assess the appropriateness of use of PCT in different settings, including emergency department (ED), intensive care unit (ICU) and internal medicine ward counting of pulmonology and infectious disease department. The preestablished answers included at first step a dichotomous choice (i.e. yes or no) with a secondary choice that motivated the answer based on expert opinion, relevant clinical trials or both of them. During the second round, the panel of expert answered the questions anonymously without any influence of group's opinions. After a free discussion and reading the answers, a third round was conducted in which the experts reviewed their answers and had the opportunity to change it according with the view of the board's response.

Consensus was defined with a cutoff of agreement $\geq 80\%$. According with the agreement reached on indication and level of evidence, the recommendation for use or not use of PCT in different scenarios was classified with three levels of certainty following the National Institute for Health and Clinical Excellence guidelines: (i) “must” and “must not”, (ii) “should” and “should not” and (iii) “could” [17].

Table 1: List of all members of the expert board.

Name	Affiliation	Role	Field of expertise
Massimo Antonelli	UOC Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica (UOC) Fondazione Policlinico Universitario A. Gemelli-Università Cattolica del Sacro Cuore	Expert	Intensive care medicine
Francesco Bruno Arturo Blasi	Department of Pathophysiology and Transplantation, Università degli studi di Milano, UOC broncopneumologia, IRCCS Fondazione, “Cà Granda” Policlinico, Milan, Italy	Expert	Pulmonology
Ivo Casagrande	Dipartimento di Emergenza ed Accettazione, Azienda Ospedaliera “Santi Antonio e Biagio e C. Arrigo”, Alessandria	Expert	Emergency
Arturo Chieregato	Neuroranimazione, Ospedale Niguarda Ca’ Granda, Milano	Expert	Neurological intensive care medicine
Roberto Fumagalli	Anestesia e rianimazione I, Ospedale Niguarda Ca’ Granda, Milano	Expert	Intensive care medicine
Massimo Girardis	Anestesia e Rianimazione I, Dipartimento chirurgia generale e specialità chirurgiche, Azienda Ospedaliero-Universitaria di Modena – Policlinico, Modena	Expert	Intensive care medicine
Federico Pea	Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUIUD, Udine, Italy; Department of Medicine, University of Udine, Udine, Italy	Facilitator	Clinical pharmacology
Filippo Pieralli	Subintensiva di Medicina, – Azienda Ospedaliero Universitaria Careggi – Firenze	Expert	Internal medicine
Mario Plebani	UO Medicina di Laboratorio, Azienda Ospedale-Università di Padova, Padova	Expert	Laboratory medicine
Gian Maria Rossolini	Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze e SOD Microbiologia e Virologia- Azienda Ospedaliero Universitaria Careggi – Firenze	Expert	Clinical microbiology
Massimo Sartelli	UO Chirurgia Generale, Dipartimento Chirurgia maggiore oncologica, Ospedale di Macerata, Macerata	Expert	Abdominal surgery
Bruno Viaggi	NeuroAnestesia e Rianimazione, Dipartimento di Anestesia, Azienda Ospedaliero Universitaria Careggi – Firenze	Expert	Intensive care medicine Neurological intensive care medicine
Pierluigi Viale	UO Malattie Infettive, Policlinico S.Orsola Malpighi, Bologna	Facilitator	Infectious disease
Claudio Viscoli	Clinica Malattie Infettive, Università di Genova e Ospedale Policlinico San Martino, IRCCS per l’Oncologia	Expert	Infectious disease

Results

The opinion of experts about the appropriateness of use of PCT was assessed in different clinical settings. In addition, the judgment of experts about the role of PCT as a diagnostic test, prognostic marker or an antimicrobial stewardship tool was assessed.

General considerations

- Careful evaluation of clinical and radiological findings, evaluation of severity of illness and of patient’s characteristics should be taken into proper account in order to correctly interpret PCT results.
- In patients with diagnosis of infection, PCT should be used to identify patients with poor prognosis. In this case, the trend of serum concentrations over time is more accurate than a single measurement. The usual cutoff for diagnosis of sepsis (>0.5 ng/mL) is

inaccurate and should be tailored for specific setting, site of infection and severity of underlying disease.

Emergency department [18–24]

- According with experts’ opinion, in the setting of ED and/or emergency room, PCT should be used to differentiate bacterial infections from non-bacterial ones or from non-infectious processes. Thus, PCT should be included among the available biochemical laboratory tests that may be required in the urgency/emergency settings.

Internal medicine, pulmonology and infectious disease departments [14, 21, 25–31]

- In non-critically ill patients admitted in general wards, such as internal medicine department or

infectious disease department, PCT should be used in the diagnosis of bacterial infections that may need prompt antibiotic treatment.

- In patients with community-acquired pneumonia, not fulfilling criteria for sepsis or septic shock PCT could be used to support starting of antibiotic treatment.
- In patients with acute exacerbation of chronic obstructive pulmonary disease (COPD), PCT could be useful in the diagnosis of bacterial superinfection.
- In patients with community-acquired pneumonia, not fulfilling criteria for sepsis or septic shock PCT could be used as a prognostic marker of worse outcome.
- In non-critically ill patients, a PCT increase after 48 h of antibiotic therapy must not justify treatment escalation.
- In this setting, PCT level should be monitored over time to guide treatment discontinuation.

ICU or critically ill patients [11–13, 29, 32, 33]

- In critical care medicine, PCT should be used to identify patients who need prompt antibiotic treatment.
- In addition, PCT should be used to identify patients with poor prognosis. In this latter case, PCT serum level trend must be analyzed over time. However, the time frame between two consecutive samples should be tailored on different clinical scenarios.
- In critically ill patients, a PCT increase after 48 h of antibiotic therapy must not be used to support treatment escalation.
- In ICU, PCT must be included as a tool in an algorithm for antimicrobial stewardship. Monitoring PCT levels over time must guide the discontinuation and its timing.
- In ICU, PCT must be used also in patients undergoing renal replacement therapy. However, PCT results should be interpreted cautiously and in accordance with clinical, radiological, microbiological and biochemical findings.

Surgical patients and patients with intra-abdominal infections [34–38]

- In patients undergoing surgical intervention for intra-abdominal infections, PCT should be used to guide the duration of antibiotic treatment even in presence of suspicion of postoperative peritonitis.

- Conversely, in postsurgical patients with intra-abdominal infections, a worsening trend of PCT over time should be used for supporting the need of reintervention.
- In patients with acute necrotizing pancreatitis, monitoring of PCT levels over time should be used to support the need of antibiotic escalation or discontinuation. However, in this setting, the most accurate cutoff level of PCT for supporting antibiotic escalation is still to be defined.

Discussion

In this expert consensus, we evaluated the usefulness and appropriateness of PCT measurement in different clinical scenarios. We also assessed the expert opinions about the role of PCT as a diagnostic and/or prognostic test, and as a tool for antimicrobial stewardship.

PCT is considered a helpful biomarker of bacterial infection and an early marker of sepsis in different settings, including ED, regular wards, surgical wards and ICU [11, 39]. In a previous meta-analysis including 30 reports and 3244 patients, the overall sensitivity, specificity and area under the receiver operating characteristics (ROC) curve of PCT in the diagnosis of sepsis were 0.79, 0.77 and 0.85, respectively [12]. Despite the level of evidence suggested by the literature, the panel did not reach an agreement about the role of PCT in supporting the diagnosis of pneumonia or of bacterial superinfection in patients with acute exacerbation of COPD. In this setting, it was believed that clinical criteria, patient's medical history and radiological findings should be preferred over the results of biomarkers. As stated before, this result may contribute to generate controversy in the role of PCT in the diagnosis of lower respiratory tract infections. In a previous multicenter study, patients with lower respiratory tract infections were randomized to start and discontinue antibiotics according with a PCT predefined algorithm or with clinical decision. The overall antibiotic exposure was significantly lower in patients included in the PCT group, whereas the rate of adverse outcome was similar in the two groups [14]. The results of our consensus are in the line with current Infectious Disease Society of America guidelines on hospital-acquired pneumonia or ventilator associated pneumonia, which do not consider PCT as relevant in the decision process to start antibiotic treatment in this setting [40].

An important setting of PCT use may be for antimicrobial stewardship purposes in critically ill patients in order to reduce the length of antibiotic treatment [33]. In

a randomized trial including 621 critically ill non-surgical patients, PCT guidance was useful to reduce the duration of antibiotic treatment with no adverse events [13]. Moreover, in a recent trial, 1575 ICU patients were randomized to receive a PCT-based algorithm to guide antibiotic prescription. In this group, a non-mandatory advice to discontinue antibiotics was given to all patients showing a PCT decrease $\geq 80\%$ from the baseline or in those showing a serum PCT level $\leq 0.5 \mu\text{g/L}$. This group showed significantly lower antibiotic consumption and significantly lower 28-day and 1-year mortality rates [41]. The hypothesis of the authors to explain this latter result was that PCT may enable to exclude the presence of bacterial infections leading to a more accurate diagnosis of non-infectious processes. This observation was further confirmed by a metaanalysis of randomized trials in patients with respiratory infections [42] and in secondary analysis of a Swiss randomized trial. In this latter study, among the patients with congestive heart failure randomized to the PCT group, those having a PCT lower than $0.25 \mu\text{g/L}$ showed significative lower rate of adverse outcome [18]. In addition to lowering the antibiotic consumption, several cost-effectiveness analyses demonstrated that use of PCT-based algorithms is associated to decrease of both ICU and non-ICU length of stay [43] and overall hospital cost saving ranging from £368 to £3268 [19, 43]. Lastly, in a paper evaluating a cost-impact model based on meta-analysis data of randomized trials, the estimated cost savings produced by use PCT for acute respiratory infections compared with standard care in a cohort of 1 million of people could reach \$700,000 [44].

An additional important result of this work was that in both ICU and non-ICU patients, an increase of PCT after 48 h of antibiotic treatment did not represent an indication for antibiotic escalation. In a Danish multicenter randomized trial, a PCT-based algorithm to escalate antibiotic treatment was not associated to an increased survival rate. In addition, this strategy led to higher antibiotic consumption and longer ICU stay, and therefore it is not advisable [29]. However, a recent randomized multinational trial showed that a reduction of PCT value $\geq 80\%$ from the baseline to day 4 of observation was associated to a reduction in 28-day mortality. In addition, this study evaluated short-term change of PCT as a predictor of mortality and found that patients who died within 28 days had an average increase of 30% of PCT value from baseline. By comparison, patient who survived did not show any PCT value increase. It worth to be noted that the results of this study were not available at the time when the consensus took place [31].

The optimal cutoff of PCT ensuring the best sensitivity and specificity for diagnosis of infection is still a matter

of debate. For lower respiratory tract infection, cutoffs of $0.15\text{--}0.25 \mu\text{g/L}$ are commonly considered adequate [14, 45]. However, different real-life experiences in patients with intra-abdominal infection and in ICU patients with bloodstream infection suggest that higher cutoff should be considered in these settings [32, 37]. In this latter case, higher cutoff values may be helpful to differentiate between bacterial and fungal infections [46, 47]. It is worth noting that all the available literature was produced using the high sensitive assays based on B·R·A·H·M·S· PCT antibodies, which have demonstrated strong reproducibility [48, 49]. The reproducibility of results of these assays is important especially when PCT-based algorithms are implemented for antimicrobial stewardship purposes. In this case, strict cutoff values are commonly used to decide start or discontinuation of antibiotic treatment.

Areas of further investigation and limitations

Further studies are needed to address several aspects of PCT use. Specific cutoff values should be investigated and identified particularly in intra-abdominal infections, including bacterial superinfections of acute necrotizing pancreatitis, taking into consideration the importance of a high analytical sensitivity of the assay used. Most of randomized clinical trials have been conducted in patients with acute respiratory infections. Thus, the application of specific algorithms of treatment escalation or de-escalation in other clinical scenarios has still to be evaluated. In addition, immunocompromised patients have been excluded from most clinical trials, and therefore most of the available evidences, including the findings of this consensus work, cannot be applied to immunocompromised hosts.

In conclusion, in this expert consensus, several aspects of PCT use have been evaluated and addressed. The experts considered PCT as an important marker of bacterial infection in both ICU and non-ICU patients. Its use may be appropriate in algorithms for antibiotic de-escalation and discontinuation. However, initiation or escalation of antibiotic therapy in specific scenarios, including acute respiratory infections, should not be based solely on PCT serum levels. Overall, in every clinical scenario, careful evaluation of clinical and radiological findings, evaluation of severity of illness and of patient's characteristics should be taken into proper account in order to correctly interpret PCT results.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: The entire project received an unrestricted grant by Thermo Fisher Scientific.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

- Review on Antimicrobial Resistance Antimicrobial Resistance: tackling a crisis for the health and wealth of nations. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed: January 2017.
- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P T* 2015;40:277–83.
- Fridkin S, Baggs J, Fagan R, Magill S, Pollack LA, Malpiedi P, et al. Vital signs: improving antibiotic use among hospitalized patients. *MMWR Morb Mortal Wkly Rep* 2014;63:194–200.
- Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. *Antimicrob Resist Infect Control* 2013;2:31.
- Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 2017;43:304–77.
- Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. *Crit Care Med* 2014;42:1749–55.
- Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. *Crit Care Med* 2010;38:1045–53.
- Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-receptor-like receptor 1 gene in multiple tissues in response to sepsis. *J Clin Endocrinol Metab* 2001;86:396–404.
- Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* 1993;341:515–8.
- Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. *J Clin Endocrinol Metab* 1994;79:1605–8.
- Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysis. *Crit Care* 2013;17:R291.
- Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. *Lancet Infect Dis* 2013;13:426–35.
- Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet* 2010;375:463–74.
- Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA* 2009;302:1059–66.
- Rhee C. Using procalcitonin to guide antibiotic therapy. *Open Forum Infect Dis* 2017;4:ofw249.
- Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ* 1995;311:376–80.
- National Institute for Health and Clinical Excellence (NICE) Developing NICE guidelines: the manual. Available at: <https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview>. Accessed: January 2017.
- Schuetz P, Kutz A, Grolimund E, Haubitz S, Demann D, Vogeli A, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. *Int J Cardiol* 2014;175:464–72.
- Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2015;19:v–xxv, 1–236.
- Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. *J Gen Intern Med* 2013;28:1157–64.
- Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2017;10:CD007498.
- Drozdz D, Schwarz S, Kutz A, Grolimund E, Rast AC, Steiner D, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. *BMC Med* 2015;13:104.
- McCluskey SM, Schuetz P, Abers MS, Bearnot B, Morales ME, Hoffman D, et al. Serial procalcitonin as a predictor of bacteraemia and need for intensive care unit care in adults with pneumonia, including those with highest severity: a prospective cohort study. *Open Forum Infect Dis* 2017;4:ofw238.
- van der Does Y, Rood PP, Haagsma JA, Patka P, van Gorp EC, Limper M. Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review. *Am J Emerg Med* 2016;34:1286–93.
- Liew YX, Chlebicki MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). *Eur J Clin Microbiol Infect Dis* 2011;30:853–5.
- Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. *Respirology* 2011;16:819–24.
- Lin C, Pang Q. Meta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease. *Clin Respir J* 2018;12:10–5.

28. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. *Arch Intern Med* 2008;168:2000–7; discussion 2007–8.
29. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. *Crit Care Med* 2011;39:2048–58.
30. Huang HB, Peng JM, Weng L, Wang CY, Jiang W, Du B. Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis. *Ann Intensive Care* 2017;7:114.
31. Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin MONitoring SEpsis (MOSES) Study. *Crit Care Med* 2017;45:781–9.
32. Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. *Crit Care Med* 2006;34:102–7.
33. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. *Crit Care Med* 2011;39:1792–9.
34. Svoboda P, Kantorova I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? *Hepatogastroenterology* 2007;54:359–63.
35. Novotny AR, Emmanuel K, Hueser N, Knebel C, Kriner M, Ulm K, et al. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. *Surgery* 2009;145:20–6.
36. Huang TS, Huang SS, Shyu YC, Lee CH, Jwo SC, Chen PJ, et al. A procalcitonin-based algorithm to guide antibiotic therapy in secondary peritonitis following emergency surgery: a prospective study with propensity score matching analysis. *PLoS One* 2014;9:e90539.
37. Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, et al. Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy. *Eur J Surg Oncol* 2016;42:234–43.
38. Rau BM, Kemppainen EA, Gumbs AA, Buchler MW, Wegscheider K, Bassi C, et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. *Ann Surg* 2007;245:745–54.
39. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. *Chest* 2007;131:9–19.
40. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016;63:e61–111.
41. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis* 2016;16:819–27.
42. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis* 2018;18:95–107.
43. Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Effect of procalcitonin testing on health-care utilization and costs in critically ill patients in the United States. *Chest* 2017;151:23–33.
44. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. *Clin Chem Lab Med* 2015;53:583–92.
45. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med* 2011;9:107.
46. Giacobbe DR, Mikulska M, Tumbarello M, Furfaro E, Spadaro M, Losito AR, et al. Combined use of serum (1,3)-beta-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. *Crit Care* 2017;21:176.
47. Pieralli F, Corbo L, Torrigiani A, Mannini D, Antonielli E, Mancini A, et al. Usefulness of procalcitonin in differentiating Candida and bacterial blood stream infections in critically ill septic patients outside the intensive care unit. *Intern Emerg Med* 2017;12:629–35.
48. Hausfater P, Brochet C, Freund Y, Charles V, Bernard M. Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays. *Clin Chem Lab Med* 2010;48:501–4.
49. Sanders RJ, Schoorl M, Dekker E, Snijders D, Boersma WG, Ten Boekel E. Evaluation of a new procalcitonin assay for the Siemens ADVIA Centaur with the established method on the B.R.A.H.M.S Kryptor. *Clin Lab* 2011;57:415–20.